new glp 1 agonist In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron GLP-1 Agonists: A Comprehensive Overview

What are dual and triple GLP-1 agonists

[38] suggested that obese patients treated with liraglutide or Semaglutide showed a marked reduction in self-reported alcohol intake after 36 months, particularly among high consumers

Treatment discontinuation due to adverse events occurred in approximately 5-10% of orforglipron-treated participants

MW: Writing review and editing, Conceptualization

The roller coaster ride to the first GLP-1 obesity drug While approved first as a drug for diabetes, very early on in its development, when Knudsen first began work on liraglutide she wondered if the same drug could also be used as a treatment of obesity (Molteni, Chen)

Microglia function in the central nervous system during health and neurodegeneration